On August 25, GENSCRIPT BIO rose 3.07% in regular trading, trading at HK$33.7/share, with turnover of HK$121 million, rebounding notably from the prior session's 4.12% pullback.

On the news front, the company continues to attract concentrated institutional upgrades following its interim results release. JPMorgan raised its target price to HK$35, Huatai Securities set a target of HK$36.08, while Bank of Communications International and CICC both raised targets above HK$32, all maintaining buy ratings. The company reported H1 revenue of US$404 million, up 27.3% year-over-year, with AIDD-related business doubling on an annual basis. Adjusted net profit surged 203.3% to US$62.5 million. The life sciences segment delivered revenue of US$319 million with adjusted operating profit growing 102.8%, driven by AI-powered drug discovery demand accelerating the gene-to-protein business and improved capacity utilization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)